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Viruses
• Viruses consist of genetic material (DNA, 
positive RNA or negative RNA) packaged 
into a nucleocapsid and/or membrane. 
• Unlike other infectious agents, viruses are 
so small that they depend on the host cell 
machinery for protein synthesis, energy 
and replication. 
• Classification of viruses is based on their 
genetic material, envelope and/or 
nucleocapsid, size and morphology. 
Viral replication consists of several steps:
• (1) adsorption to and penetration into 
susceptible host cells; 
• (2) uncoating of viral nucleic acid; 
• (3) synthesis of early regulatory proteins, 
eg, nucleic acid polymerases; 
• (4) synthesis of RNA or DNA; 
• (5) synthesis of late, structural proteins; 
• (6) assembly (maturation) of viral particles;
• (7) release from the cell. Antiviral agents can 
potentially target any of these steps



Retrovirus replicative cycle
• The retroviruses, like HIV, bind to the host cell membrane 
and enter the cell by endocytosis. 
• Their RNA is reverse transcribed into DNA, which is 
integrated in the host cell genome. 
• The integrated viral DNA is transcribed into new viral RNA 
and mRNA for viral protein synthesis. 
• The assembly of viral components occurs in the cytoplasm 
and the new viruses are released from the host cell by 
budding.
• HIV therapy involves a combination of antiretroviral drugs
(HAART therapy): 
– 2 NRTIs
– or a NRTI + a NNRTI 
– or a NRTI + a protease inhibitor.
• Recently, immunotherapy (IL-2, interferon) for HIV has 
gained interest. However, there is still no proof of clinical 
benefit. 

NRTI
• Nucleoside reverse transcriptase inhibitors (NRTIs) are 
analogues of the natural RNA and DNA nucleotides. 
• Zidovudine (AZT) e.g. is a thymidine analogue. This drug is 
phosphorylated three times, like its natural analogue and 
together they compete for the reverse transcriptase. 
• The triphosphate drug inhibits the reverse transcriptase. 
However when transcription still occurs, the triphosphate drug 
is built in the DNA. The incorporation of nucleoside analogues 
aborts DNA synthesis and destabilizes the viral double DNA 
strand. 
• Zidovudine was the first antiretroviral agent. 
• In high doses it can lead to severe myelotoxicity, but in normal 
doses it causes only some initial gastrointestinal complaints.
• Zidovudine is a favorable NRTI because it lacks neurotoxicity
and good CNS penetration.
Lamivudine (3TC) is another well-tolerated nucleoside 
analogue. Its disadvantage is a rapid development of 
resistance. Lamivudine is also effective against Hepatitis B 
viruses. 

NNRTI
• Nevirapine, delavirdine and efavirenz Non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). 
• They bind directly and non-competitively to the reverse 
transcriptase of HIV and block the polymerase activity by 
deregulating the catalytic part of the enzyme. 
• In contrast to NRTIs, NNRTIs do not require activation 
within the cell. NNRTIs are non-competitive inhibitors of 
mainly HIV-1 reverse transcriptase. 
• NNRTIs were introduced between 1996-1998. On their own, 
they are not so potent, but in combination with a NRTI they 
are extremely effective.
• NNRTIs are metabolized by cP4503A enzymes in the liver 
and thus can interact with many drugs such as, 
astemazole, midazolam, cyclosporine, rifampin and 
erythromycin.
• Nevirapine can cause serious hepatotoxicity. Therefore, 
liver functions need to be monitored during therapy. 

Protease inhibitors
• Saquinavir, ritonavir and indinavir are well-known 
protease inhibitors in the treatment of HIV-infection. 
• These drugs inhibit the enzymes (proteases) that split 
viral proteins. In this way the formation of essential 
polypeptides and enzymes is decreased. 
• This leads to production of immature and non-
functional new viruses, which are not able to infect 
new cells.
• All protease inhibitors cause gastrointestinal side 
effects. Moreover, long-term therapy can be implicated 
in lipodystrophy and dyslipidemia. 
• All protease inhibitors are inhibitors of the CYP3A4 
system and thus interact with numerous other drugs. 
Currently Available Antiretroviral Agents
Agent Class ESO Comments
Abacavir NRTI 300 mg 
bid
Rash, 
hypersensitivit
y reaction, 
nausea
Do not rechallenge
after 
hypersensitivity 
reaction
Amprenavir PI 1200 mg 
bid
Separate 
dosing from 
didanosine or 
antacids by 1 
hour. Avoid 
high-fat meals.
Rash, diarrhea, 
nausea
See footnote 2 for 
concurrent drug 
contraindications. 
Oral solution 
contraindicated in 
young children and 
pregnant women.
Delavirdine NNRTI 400 mg 
tid
Separate 
dosing from 
didanosine or 
antacids by 1 
hour.
Rash, liver 
function 
abnormalities
Teratogenic; see 
footnote 2 for 
concurrent drug 
contraindications
Agent Class ESO Comments
Didanosine3 NRTI 150–200 mg 
bid, Enteric-
coated: 250–
400 mg qd, 
depending on 
weight
30 minutes 
before or 2 
hours after 
meals
Peripheral 
neuropathy, 
pancreatitis, 
diarrhea, 
hyperuricemia
Contains antacid; 
avoid alcohol; 
avoid concurrent 
neuropathic drugs
(eg, didanosine, 
zalcitabine, 
isoniazid)
Efavirenz NNRTI 600 mg qd Not to be 
taken with a 
fatty meal
Dizziness, 
insomnia, 
rash, 
transaminitis
Embryotoxic; see 
footnote 2 for 
concurrent drug 
contraindications
Enfuvirtide Fusion 
inhibit
or
90 mg bid Reconstitute 
for 
subcutaneou
Local 
injection site 
reactions
Refrigeration 
required
Indinavir PI 800 mg tid 1 hour before 
or 2 hours 
after a meal. 
Drink at least 
48 oz of 
liquid daily. 
Separate 
dosing with 
didanosine
by 1 hour.
Nephrolithiasi
s, nausea, 
liver function 
abnormalities
Store in original 
container, which 
contains dessicant; 
see footnote 2 for 
concurrent drug 
contraindications
Lamivudine3 NRTI 150 mg bid or 
300 mg qd, 
depending on 
weight
Nausea, 
headache, 
fatigue
Active against HBV 
as well as HIV-1
Lopinavir/rit
onavir
PI/PI 400 mg/I00 
mg bid
With food. 
Separate 
dosing with 
didanosine
by 1 hour.
Diarrhea, 
abdominal 
pain, nausea
The oral solution 
contains alcohol; 
store capsules and 
solution in 
refrigerator; see 
footnote 2 for 
concurrent drug 
contraindications.
Nelfinavir PI 750 mg tid or 
1250 mg bid
With food Diarrhea, 
nausea, 
flatulence
See footnote 2 for 
concurrent drug 
contraindications
Nevirapine NNRTI 200 mg bid Rash, 
hepatitis, 
nausea, 
headache
Dose-escalate from 
200 mg qd over 14 
days to decrease 
frequency of rash. 
Avoid concurrent 
use with 
ketoconazole, 
methadone, and 
oral contraceptives.
Ritonavir PI 600 mg bid With food. 
Separate 
dosing with 
didanosine by 
2 hours.
Nausea, 
diarrhea, 
paresthesias, 
hepatitis
Dose-escalate over 5–10 
days to improve tolerance. 
In combination with 
saquinavir (400 mg bid), 
use 400 mg bid ritonavir. 
Refrigerate capsules but 
not oral solution. See 
footnote 2 for concurrent 
drug contraindications; 
avoid concurrent oral 
contraceptives.
Saquinavi
r hard gel
PI 600 mg tid
or 400 mg 
bid with 
ritonavir
400 mg bid
Within 2 hours 
of a full meal
Nausea, 
diarrhea, 
rhinitis
Refrigeration 
recommended; see 
footnote 2 for concurrent 
drug contraindications.
Saquinavi
r soft gel
PI 1200 mg 
tid or 1800 
mg bid or 
1600 mg 
qd with 
ritonavir
100 mg qd
Within 2 hours 
of a full meal
Nausea, 
diarrhea, 
abdominal 
pain, 
dyspepsia
Refrigeration 
recommended; see 
footnote 2 for concurrent 
drug contraindications.
Currently Available Antiretroviral AgentsStavudine
3
NRTI 30–40 
mg bid, 
dependi
ng on 
weight
Peripheral 
neuropathy, 
stomatitis
Avoid concurrent 
neuropathic drugs ( eg, 
didanosine, zalcitabine, 
isoniazid); avoid 
concurrent use with 
zidovudine
Tenofovir4 Nucle
otide 
inhibi
tor
300 mg 
qd
With a meal. 
Separate 
dosing with 
didanosine by 
1–2 hours
Nausea, 
vomiting, 
diarrhea, 
flatulence
Zalcitabin
e3
NRTI 0.75 mg 
tid
Avoid 
administration 
with antacids 
or food
Peripheral 
neuropathy; 
oral 
ulcerations
Avoid concurrent 
neuropathic drugs (eg, 
didanosine, stavudine, 
isoniazid)
Zidovudin
e3
NRTI 200 mg 
tid or 
300 mg 
bid
Anemia, 
neutropenia, 
nausea, 
insomnia
Avoid concurrent 
myelosuppressive drugs
(eg, ganciclovir, ribavirin)
• The following drugs are contraindicated as 
concurrent medications: astemizole, 
terfenadine, dihydroergotamine, cisapride, 
pimozide, midazolam, triazolam, 
flecainide, propafenone, rifampin, 
lovastatin, simvastatin, St. John's wort.
Drug Interactions Pertaining to Two-Drug Antiretroviral 
Combinations.
Agent Drugs That Will Increase Its 
Serum Levels
Drugs That Will Decrease Its 
Serum Levels
Amprenavir Abacavir, delavirdine, 
indinavir, lopinavir, 
ritonavir, zidovudine
Didanosine, efavirenz, 
nevirapine, saquinavir
Delavirdine Saquinavir Didanosine, nelfinavir
Didanosine Tenofovir Delavirdine
Efavirenz Ritonavir
Indinavir Delavirdine, lopinavir, 
nelfinavir, zidovudine
Amprenavir, delavirdine, 
efavirenz, nevirapine, 
ritonavir
Lamivudine Nelfinavir
Lopinavir Delavirdine, ritonavir
Nelfinavir Delavirdine, efavirenz, 
ritonavir, saquinavir
Ritonavir Delavirdine, efavirenz Didanosine, indinavir, 
zidovudine
Saquinavir Delavirdine, lopinavir, 
nelfinavir, ritonavir
Efavirenz, nevirapine

Influenza virus
• The influenza viruses are endocytosed in the 
host cell and are uncoated in the cytoplasm.
• Transcription and replication happens in the 
host cell nucleus. 
• After the assembly of the viral RNA and protein 
in the cytoplasm, the new virus buds from the 
host cell plasma membrane. 

Amantadine
• Amantadine. Their exact mechanism of action as 
antiviral drug is unknown. 
• Amantadine inhibits an early step in viral replication: 
penetration of the virus into the host cell.
• It also prevents the uncoating of the virus, thereby 
inhibiting the release of viral genetic material.
• Secondly, amantadine might also interfere with the 
last step in the replication cycle, thereby inhibiting viral 
assembly.
• Amantadine is well absorbed orally and has a large 
volume of distribution. The drug is excreted largely 
unchanged in urine. Common side effects include 
gastrointestinal problems and CNS complaints.
• High doses can be neurotoxic and result in seizures or 
coma. 

Neuraminidase inhibitors
• Oseltamivir is a relatively new drug. It is a 
prodrug of a selective inhibitor of 
neuraminidase, an enzyme and glycoprotein at 
the surface of influenza virus. 
• Neuraminidase stimulates the penetration of the 
virus and facilitates the release of newly formed 
viruses. Oseltamivir thus causes viral 
aggregation at the cell surface and reduces 
viral replication. 
• The drug is registered for the prevention and 
treatment of influenza A and B virus infections. 
Oseltamivir is generally well-tolerated. 

Herpes virus
• Herpes viruses have an envelope and carry DNA in 
the capsid. 
• Their replication begins with recognition by the host 
cell and is followed by fusion of the envelope with the 
cell membrane and release of the nucleocapsid. 
• Inside the host cell, the nucleocapsid fuses with the 
nuclear membrane. Inside the nucleus the viral DNA is 
transcribed and replicated via viral DNA polymerase.
• In the meantime viral proteins are synthesized and 
assembly occurs in the nucleus. The nuclear 
membrane is used as envelope. The new viruses are 
released via exocytosis or by lysis of the host cell 

Acyclovir
• Acyclovir and valaciclovir belong to the group of 
nucleoside inhibitors of herpes viruses. 
• Acyclovir is converted in the cell into active acyclovir 
triphosphate by the viral enzyme thymidine kinase. 
The triphosphate form competitively inhibits the viral 
DNA polymerase. 
• This leads to a blockade of the viral DNA synthesis 
and thus of the viral replication.
• The related drugs ganciclovir and valganciclovir are 
drug of choice in cytomegalovirus infection.
Half-life: t1/2= 2,4 h 
Agents to Treat or Prevent Herpes Simplex Virus (HSV) 
and Varicella-Zoster Virus (VZV) Infections.
Agent Route Use Recommended Adult 
Dosage and Regimen
First episode genital herpes 400 mg tid or 200 mg five 
times daily
Recurrent genital herpes 400 mg tid or 200 mg five 
times daily or 800 mg bid
Genital herpes suppression 400 mg bid 
Herpes proctitis 400 mg five times daily
Mucocutaneous herpes in the 
immunocompromised host
400 mg five times daily
Varicella 20 mg/kg (maximum 800 
mg) four times daily 
Zoster 800 mg five times daily
Severe HSV infection 5 mg/kg q8h
Herpes encephalitis 10–15 mg/kg q8h
Neonatal HSV infection 20 mg/kg q8h
Varicella or zoster in the 10 mg/kg q8h
IV
OralAcyclovir
Agents to Treat or Prevent Herpes Simplex Virus (HSV) 
and Varicella-Zoster Virus (VZV) Infections.
Agent Route Use Recommended Adult Dosage 
and Regimen
First episode genital herpes 250 mg tid
Recurrent genital herpes 125 mg bid 
Genital herpes suppression 250 mg bid 
Zoster 500 mg tid
First episode genital herpes 1 g bid 
Recurrent genital herpes 500 mg bid 
Genital herpes suppression 500 mg daily or twice daily
Zoster 1 g tid
Foscarnet1 Intrave
nous
Acyclovir-resistant HSV and 
VZV infections
40 mg/kg q8-12h
Penciclovir Topical Recurrent herpes labialis Thin film covering lesion every 2 
hours 
Herpes keratitis 1 drop every 2 hours
Acyclovir-resistant HSV 
infection
Thin film covering lesion five 
times daily 
Trifluridine Topical
Valacyclovi
r1
Oral
Famciclovi
r1
Oral

Hepatitis B virus
• After entry into the hepatocyte, the DNA of the 
hepatitis virus is brought to the nucleus. 
• There the viral DNA is transcribed and the 
resulting mRNA is transported to the cytoplasm. 
Here the mRNA is either reverse transcribed 
into viral DNA or translated into viral proteins.
• The viral DNA and proteins are assembled and 
enveloped before exocytosis. 

Interferons
• Interferons (IFN-a 2a and IFN-a 2b) are cytokines that 
possess antiviral and immunomodulating actions. 
• Interferons “mark” infected cells by binding to the cell 
membrane of virus-infected cells, initiate complex 
actions inside the cell that prevent viral replication and 
activate the immune system.
• Interferons are administered via intramuscular, 
intravenous or subcutaneous injection.
• Elimination from the blood relates to distribution, 
cellular uptake and catabolism in liver and kidney.
• Adverse effects of interferons are acute influenza-like 
symptoms. In higher doses, interferons can cause 
myelosuppression. 

